Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026)
Denali Therapeutics (DNLI) reported Return on Capital Employed of 49.95% for Q1 2026, down 810.0% year-over-year from 7.04% in Q1 2025, and up 9.88% on a QoQ basis from 55.43% in Q4 2025.
Denali Therapeutics (DNLI) has 9 years of Return on Capital Employed data on file, last reported at 49.95% in Q1 2026.
- Quarterly Return on Capital Employed fell 810.0% year-over-year to 49.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.95% (down 810.0% YoY) and the FY2025 annual result came in at 47.83%, down 588.0% from the prior year.
- Return on Capital Employed advanced to 49.95% in Q1 2026 per DNLI's latest filing, from 55.43% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.67% in Q2 2023 and bottomed at 55.43% in Q4 2025.
- The 5-year median for Return on Capital Employed is 34.77% (2022), against an average of 34.06%.
- The widest annual swing landed in 2022, when Return on Capital Employed sank 3653 bps; it then soared 2278 bps in 2024.
- Tracing DNLI's Return on Capital Employed over 5 years: stood at 34.77% in 2022, then jumped by 49 bps to 17.6% in 2023, then plunged by 111 bps to 37.15% in 2024, then sank by 49 bps to 55.43% in 2025, then gained by 10 bps to 49.95% in 2026.
- Per Business Quant, the three latest DNLI Return on Capital Employed figures stand at 49.95% (Q1 2026), 55.43% (Q4 2025), and 53.67% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -49.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.95% |
| Dec 31, 2025 | -55.43% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -47.31% |
| Mar 31, 2025 | -41.86% |
| Dec 31, 2024 | -37.15% |
| Sep 30, 2024 | -35.23% |
| Jun 30, 2024 | -32.76% |
| Mar 31, 2024 | -15.07% |
| Dec 31, 2023 | -17.60% |
| Sep 30, 2023 | -14.12% |
| Jun 30, 2023 | -12.67% |
| Mar 31, 2023 | -37.85% |
| Dec 31, 2022 | -34.77% |
| Sep 30, 2022 | -34.75% |
| Jun 30, 2022 | -30.32% |
| Mar 31, 2022 | -28.50% |
| Dec 31, 2021 | -28.20% |
| Sep 30, 2021 | 1.79% |
| Jun 30, 2021 | 3.45% |
| Mar 31, 2021 | 3.38% |
| Dec 31, 2020 | 4.96% |
| Sep 30, 2020 | -31.74% |
| Jun 30, 2020 | -37.37% |
| Mar 31, 2020 | -39.98% |
| Dec 31, 2019 | -40.01% |
| Sep 30, 2019 | -14.07% |
| Jun 30, 2019 | -11.22% |
| Mar 31, 2019 | -10.08% |
| Dec 31, 2018 | -8.13% |
| Sep 30, 2018 | -27.46% |
| Jun 30, 2018 | -22.95% |
| Mar 31, 2018 | -17.66% |